Cargando…
The Immunotherapy Landscape in Adrenocortical Cancer
SIMPLE SUMMARY: Adrenocortical carcinoma is a rare and life-threatening cancer originating from the adrenal glands. Although aggressive surgical interventions may cure this cancer when detected at early stages, treatments for advanced or metastatic disease are limited and often unable to shrink or c...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199088/ https://www.ncbi.nlm.nih.gov/pubmed/34071333 http://dx.doi.org/10.3390/cancers13112660 |
_version_ | 1783707294008082432 |
---|---|
author | Pegna, Guillaume J. Roper, Nitin Kaplan, Rosandra N. Bergsland, Emily Kiseljak-Vassiliades, Katja Habra, Mouhammed Amir Pommier, Yves Del Rivero, Jaydira |
author_facet | Pegna, Guillaume J. Roper, Nitin Kaplan, Rosandra N. Bergsland, Emily Kiseljak-Vassiliades, Katja Habra, Mouhammed Amir Pommier, Yves Del Rivero, Jaydira |
author_sort | Pegna, Guillaume J. |
collection | PubMed |
description | SIMPLE SUMMARY: Adrenocortical carcinoma is a rare and life-threatening cancer originating from the adrenal glands. Although aggressive surgical interventions may cure this cancer when detected at early stages, treatments for advanced or metastatic disease are limited and often unable to shrink or control the growth of this tumor. Research into new treatments is needed for adrenal cortical carcinoma and other rare cancers. For cancers and other medical conditions, new therapies can be tested through clinical trials, in which patients are treated with new medications or innovative medication combinations. Among these novel and innovative treatments are immunotherapies. These therapies are playing an increasingly important role in the treatment of multiple different cancers. This article focuses on the various immunotherapies that have been, currently are, or will be tested in clinical trials for the treatment of adrenocortical carcinoma. ABSTRACT: Adrenocortical carcinoma (ACC) is a rare cancer of the adrenal gland that is frequently associated with excess production of adrenal hormones. Although surgical resection may be curative in early-stage disease, few effective therapeutic options exist in the inoperable advanced or metastatic setting. Immunotherapies, inclusive of a broad array of immune-activating and immune-modulating antineoplastic agents, have demonstrated clinical benefit in a wide range of solid and hematologic malignancies. Due to the broad activity across multiple cancer types, there is significant interest in testing these agents in rare tumors, including ACC. Multiple clinical trials evaluating immunotherapies for the treatment of ACC have been conducted, and many more are ongoing or planned. Immunotherapies that have been evaluated in clinical trials for ACC include the immune checkpoint inhibitors pembrolizumab, nivolumab, and avelumab. Other immunotherapies that have been evaluated include the monoclonal antibodies figitumumab and cixutumumab directed against the ACC-expressed insulin-like growth factor 1 (IGF-1) receptor, the recombinant cytotoxin interleukin-13-pseudomonas exotoxin A, and autologous tumor lysate dendritic cell vaccine. These agents have shown modest clinical activity, although nonzero in the case of the immune checkpoint inhibitors. Clinical trials are ongoing to evaluate whether this clinical activity may be augmented through combinations with other immune-acting agents or targeted therapies. |
format | Online Article Text |
id | pubmed-8199088 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81990882021-06-14 The Immunotherapy Landscape in Adrenocortical Cancer Pegna, Guillaume J. Roper, Nitin Kaplan, Rosandra N. Bergsland, Emily Kiseljak-Vassiliades, Katja Habra, Mouhammed Amir Pommier, Yves Del Rivero, Jaydira Cancers (Basel) Review SIMPLE SUMMARY: Adrenocortical carcinoma is a rare and life-threatening cancer originating from the adrenal glands. Although aggressive surgical interventions may cure this cancer when detected at early stages, treatments for advanced or metastatic disease are limited and often unable to shrink or control the growth of this tumor. Research into new treatments is needed for adrenal cortical carcinoma and other rare cancers. For cancers and other medical conditions, new therapies can be tested through clinical trials, in which patients are treated with new medications or innovative medication combinations. Among these novel and innovative treatments are immunotherapies. These therapies are playing an increasingly important role in the treatment of multiple different cancers. This article focuses on the various immunotherapies that have been, currently are, or will be tested in clinical trials for the treatment of adrenocortical carcinoma. ABSTRACT: Adrenocortical carcinoma (ACC) is a rare cancer of the adrenal gland that is frequently associated with excess production of adrenal hormones. Although surgical resection may be curative in early-stage disease, few effective therapeutic options exist in the inoperable advanced or metastatic setting. Immunotherapies, inclusive of a broad array of immune-activating and immune-modulating antineoplastic agents, have demonstrated clinical benefit in a wide range of solid and hematologic malignancies. Due to the broad activity across multiple cancer types, there is significant interest in testing these agents in rare tumors, including ACC. Multiple clinical trials evaluating immunotherapies for the treatment of ACC have been conducted, and many more are ongoing or planned. Immunotherapies that have been evaluated in clinical trials for ACC include the immune checkpoint inhibitors pembrolizumab, nivolumab, and avelumab. Other immunotherapies that have been evaluated include the monoclonal antibodies figitumumab and cixutumumab directed against the ACC-expressed insulin-like growth factor 1 (IGF-1) receptor, the recombinant cytotoxin interleukin-13-pseudomonas exotoxin A, and autologous tumor lysate dendritic cell vaccine. These agents have shown modest clinical activity, although nonzero in the case of the immune checkpoint inhibitors. Clinical trials are ongoing to evaluate whether this clinical activity may be augmented through combinations with other immune-acting agents or targeted therapies. MDPI 2021-05-28 /pmc/articles/PMC8199088/ /pubmed/34071333 http://dx.doi.org/10.3390/cancers13112660 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pegna, Guillaume J. Roper, Nitin Kaplan, Rosandra N. Bergsland, Emily Kiseljak-Vassiliades, Katja Habra, Mouhammed Amir Pommier, Yves Del Rivero, Jaydira The Immunotherapy Landscape in Adrenocortical Cancer |
title | The Immunotherapy Landscape in Adrenocortical Cancer |
title_full | The Immunotherapy Landscape in Adrenocortical Cancer |
title_fullStr | The Immunotherapy Landscape in Adrenocortical Cancer |
title_full_unstemmed | The Immunotherapy Landscape in Adrenocortical Cancer |
title_short | The Immunotherapy Landscape in Adrenocortical Cancer |
title_sort | immunotherapy landscape in adrenocortical cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199088/ https://www.ncbi.nlm.nih.gov/pubmed/34071333 http://dx.doi.org/10.3390/cancers13112660 |
work_keys_str_mv | AT pegnaguillaumej theimmunotherapylandscapeinadrenocorticalcancer AT ropernitin theimmunotherapylandscapeinadrenocorticalcancer AT kaplanrosandran theimmunotherapylandscapeinadrenocorticalcancer AT bergslandemily theimmunotherapylandscapeinadrenocorticalcancer AT kiseljakvassiliadeskatja theimmunotherapylandscapeinadrenocorticalcancer AT habramouhammedamir theimmunotherapylandscapeinadrenocorticalcancer AT pommieryves theimmunotherapylandscapeinadrenocorticalcancer AT delriverojaydira theimmunotherapylandscapeinadrenocorticalcancer AT pegnaguillaumej immunotherapylandscapeinadrenocorticalcancer AT ropernitin immunotherapylandscapeinadrenocorticalcancer AT kaplanrosandran immunotherapylandscapeinadrenocorticalcancer AT bergslandemily immunotherapylandscapeinadrenocorticalcancer AT kiseljakvassiliadeskatja immunotherapylandscapeinadrenocorticalcancer AT habramouhammedamir immunotherapylandscapeinadrenocorticalcancer AT pommieryves immunotherapylandscapeinadrenocorticalcancer AT delriverojaydira immunotherapylandscapeinadrenocorticalcancer |